MCO delivered a high-quality Q1 with revenue of $2.08B, adjusted EPS of $4.33, MIS revenue of $1.14B, and MA revenue of $926M. The first draft underplayed two transcript-level points: MA ARR was the real subscription-health signal at $3.6B and +8%, while MA organic revenue growth was only 6% because transaction revenue and the Regulatory Solutions divestiture distort the bridge. On MIS, the company is holding guidance because issuance was softer than expected after March volatility even though spreads remain attractive. The right read is positive but nuanced: ratings upside, MA recurring durability, low-end EPS guide language, and an explicit buyback raise.

Key Metrics Trends

Metric	Q1 2024	Q2 2024	Q3 2024	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Total revenue	$1.8B	$1.8B	$1.8B	$1.7B	$1.9B	$1.9B	$2.0B	$1.9B	$2.1B
Total revenue YoY %	-	-	-	-	+7.7%	+4.5%	+10.7%	+13.0%	+8.1%
MIS revenue	$979M	$1.0B	$974M	$801M	$1.1B	$1.0B	$1.1B	$937M	$1.1B
MIS revenue YoY %	-	-	-	-	+7.9%	-0.5%	+12.0%	+17.0%	+8.0%
MA external revenue	$799M	$802M	$831M	$863M	$859M	$888M	$909M	$943M	$926M
MA external revenue YoY %	-	-	-	-	+7.5%	+10.7%	+9.4%	+9.3%	+7.8%
Corporate finance revenue	$529M	$525M	$515M	$381M	$564M	$512M	$576M	$480M	$633M
Corporate finance revenue YoY %	-	-	-	-	+6.6%	-2.5%	+11.8%	+26.0%	+12.2%
Adjusted EPS	$3.37	$3.28	$3.21	$2.62	$3.83	$3.56	$3.92	$3.64	$4.33
Adjusted EPS YoY %	-	-	-	-	+13.6%	+8.5%	+22.1%	+38.9%	+13.1%
Adjusted operating income	$668M	$672M	$614M	$440M	$735M	$680M	$749M	$582M	$803M
Adjusted operating income YoY %	-	-	-	-	+10.0%	+1.2%	+22.0%	+32.3%	+9.3%
MIS adjusted operating margin	64.6%	63.2%	59.6%	51.3%	66.0%	64.2%	65.2%	58.5%	66.7%
MIS adjusted operating margin YoY chg (bps)	-	-	-	-	+140	+100	+560	+720	+70

The Q1 trajectory improved from Q4: MIS revenue and corporate finance issuance were the main swing factors, while Moody's Analytics kept compounding at a steadier single-digit pace.

This Quarter vs Consensus

Metric	Prior / Street Frame	Actual	Variance	Read
Revenue	High-single-digit growth expected	$2.08B	+8% YoY	Clean beat quality
Adjusted EPS	Low-$4 area	$4.33	+13% YoY	Operating leverage strong
MIS revenue	Issuance recovery debated	$1.14B	+8% YoY	Cycle better than feared
MA external revenue	Mid-single-digit growth	$926M	+8% YoY	Reported growth helped by FX
MA ARR	High-single-digit growth	$3.61B	+8% YoY	Better subscription-health measure
Corporate finance	Primary transaction lever	$633M	+12% YoY	Best read-through in the quarter

The beat was not just tax or buyback math. Revenue, MIS margin, and adjusted operating income all moved in the same direction.

Guidance Deep Dive

Metric	Prior Guide	Current Guide	Change	Implication
Revenue growth	High-single-digit percent range	High-single-digit percent range	Unchanged	Company is not extrapolating Q1 issuance too aggressively
Adjusted EPS	$16.40-$17.00	$16.40-$17.00	Unchanged	Still enough after the Q1 EPS beat
MCO adjusted operating margin	52%-53%	52%-53%	Unchanged	Margin durability intact
MA organic / ARR bridge	High-single-digit organic MA guide	ARR +8%; Q1 organic revenue +6%	Bridge issue	Transaction revenue is the delta, not recurring demand
Share repurchases	About $2.0B	About $2.5B	Raised $0.5B	Capital return is the explicit raise

Note: Document search is currently in beta. Results may vary. Management maintained the operating guide despite a stronger Q1 and used repurchases as the main upward revision, which keeps the setup constructive but not overly dependent on a perfect issuance tape.

Upcoming Catalysts

Catalyst	Timing	What To Watch	Bull Case	Bear Case
Debt issuance	Q2-Q4 2026	Investment-grade and leveraged-finance activity	Refinancing and M&A support high-single-digit MIS growth	Macro volatility delays issuance
MA regulatory solutions sale	2026	Close timing and stranded cost treatment	Portfolio becomes cleaner and more recurring	Transaction mechanics distract from core growth
Share repurchases	2026	Execution against $2.5B target	EPS support rises as cash flow compounds	M&A or volatility slows buybacks
Analytics ARR	2026	Recurring growth and retention	Data and risk products keep compounding	Budget scrutiny pressures new sales

Street Q&A

Topic	Likely Street Question	Answer / Read
Guidance	Why not raise EPS after a good Q1?	The transcript points to prudence: issuance was softer than originally expected after March volatility, adjusted EPS is trending toward the low end, and management is preserving room.
Issuance	Was Q1 pull-forward?	Some timing risk exists, but management noted spreads came back in from late-March highs and funding costs remain attractive by historical standards.
Moody's Analytics	Is MA slowing?	The missing nuance was ARR. ARR was +8% to $3.6B and recurring organic growth tracks ARR better than Q1 reported organic revenue, which was dragged by transaction revenue and portfolio actions.
Capital return	Is the buyback raise meaningful?	Yes. It is the cleanest explicit guidance upgrade and supports EPS if issuance remains choppy.

Contradictions

Topic	View 1	View 2	Explainer
Q1 strength vs FY EPS caution	Revenue reached $2.08B and adjusted EPS reached $4.33.	Management still framed EPS as trending toward the low end of the unchanged $16.40-$17.00 range.	The quarter was strong, but the guide says issuance volatility still matters; do not annualize Q1.
MA reported revenue vs recurring demand	MA revenue grew to $926M.	Organic constant-currency MA revenue was only 6%, while ARR was +8% to $3.61B.	ARR is the cleaner demand signal; reported revenue overstates the simplicity of the recurring-growth story.
Ratings upside vs market caution	MIS revenue rose to $1.14B and Corporate Finance revenue rose to $633M.	Management held issuance guidance because March volatility and spread risk still matter.	The read is positive, but the company is explicitly not calling a smooth issuance recovery.

Indirect Read-Throughs

Company / Theme	Read-Through	Why It Matters
SPGI	Positive	Ratings transaction revenue strength is directly supportive for S&P Global's Ratings segment.
MSCI	Modestly positive	Risk analytics demand is healthy, but MCO's Q1 upside was more ratings-cycle driven.
Investment banks	Positive	Corporate finance issuance activity points to healthier deal and refinancing markets.
Credit markets	Constructive but volatile	The data says issuance is back, while guidance still embeds uncertainty.

Data sourced from Daloopa. Document search is currently in beta; transcript and filing snippets may vary.